ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Estrella Immunopharma Inc

Estrella Immunopharma Inc (ESLA)

0.9214
-0.0086
(-0.92%)
Closed March 30 4:00PM
0.9214
0.00
(0.00%)
After Hours: 4:25PM
Rendering Error

ESLA Financials

Financials
Rendering Error

ESLA Discussion

View Posts
81vette 81vette 1 month ago
Scanners will find this,mine did,it will only take 1 with 20k+ followers to promote this and with the current no manipulation(freely trading) it could jump up quickly
👍️0
81vette 81vette 1 month ago
new bio pharma,trading freely,72%inside!10m float,45Xs buying ave.(serious loading,on 1st trial news)
👍️0
81vette 81vette 1 month ago
Golden cross https://stockcharts.com/h-sc/ui?s=esla
👍️0
81vette 81vette 1 month ago
Buys 2x the sells,nearly no dark trades https://ih.advfn.com/stock-market/NASDAQ/estrella-immunopharma-ESLA/trades
👍️0
81vette 81vette 1 month ago
Nice chart,moving freely is rare!
In 10k@1.55
👍️0
tedpeele tedpeele 1 month ago
ESLA $16 12 month price target, news today - moving forward
👍️0
tedpeele tedpeele 1 month ago
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
4:46 PM ET 2/19/25 | BusinessWire

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
EMERYVILLE, Calif.--(BUSINESS WIRE)--February 19, 2025--

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS(R) T-cell therapies to treat cancer and autoimmune diseases, today announced that D. Boral Capital LLC ("D. Boral Capital"), a leading investment bank, has initiated coverage on the Company, assigning a Buy rating to Estrella and established a 12-month price target of $16.00.

Valuation Highlights
-- D. Boral Capital's analysis focuses on the development of EB103 in B-cell
Non-Hodgkin's Lymphoma, emphasizing Estrella's ARTEMIS(R) T-cell
engineering platform that utilizes cellular mechanisms which closely
resemble those of endogenous T-cell receptors, producing a more natural
and regulated immune response.

-- The derived 12-month price target of $16.00 underscores market confidence
in Estrella's potential to capture significant market share in
immuno-oncology.

-- The models incorporate a 30% probability of success along with a 30%
discount rate, reflecting the early stage of Estrella's clinical
development.
👍️0
Monksdream Monksdream 3 months ago
ESLA, under $2
👍️0
glenn1919 glenn1919 4 months ago
ESLA.......................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 months ago
ESLA..........................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 months ago
ESLA...................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 months ago
ESLA......................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 months ago
ESLA....................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 months ago
ESLA........................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 6 months ago
ESLA.........................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 8 months ago
ESLA.....................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783
👍️0

Your Recent History

Delayed Upgrade Clock